Table 2.
Effects of cdh6MO Injection on Cranial and Lateral Line Ganglia Development
| gV/Ad (%) | sag (%) | gX (%) | gP (%) | |
|---|---|---|---|---|
| 32 hpf anti-Hu | ||||
| Control (n=30) | 3.3 | 6.7 | 0 | |
| cdh6MO (n=30) | 83.3 | 83.3 | 20 | |
| 32 hpf zn5 | ||||
| Control (n=30) | 13.3 | 10 | ||
| cdh6MO (n=30) | 83.3 | 80 | ||
| 50 hpf anti-Hu | ||||
| Control (n=30) | 10 | 6.7 | 16.7 | 3.3 |
| 5-misMO (n=24) | 4.2 | 12.5 | 8.3 | 8.3 |
| cdh6MO (n=30) | 56.7 | 66.7 | 93.3 | 20 |
| cdh6MO+mRNA (n=12) | 0 | 16.7 | 8.3 | 0 |
| 50 hpf zn5 | ||||
| Control (n=30) | 0 | 13.3 | 6.7 | |
| 5-misMO (n=30) | 10 | 16.7 | 10 | |
| cdh6MO (n=28) | 50 | 71.4 | 85.7 | |
| cdh6MO+mRNA (n=1) | 0 | 25.0 | 8.3 |
n, number of ganglia examined. %, percentages of obviously abnormally formed ganglia (e.g. smaller size, altered shape, and/or reduced staining compared to the majority of control embryos).